Home
    • Plans Blog Contact
    CorMedix Inc logo

    CorMedix Inc

    CRMD
    Last price US$7.87
    Market cap US$657.8m
    12M price change -31.62%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    CorMedix Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for CorMedix Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 14, 2026

    Quarterly result summary

    Revenue was $127.4M (reported); EPS was $0.48 (reported).

    Revenue $127.4M reported
    EPS $0.48 reported
    Operating income $63.7M +216% YoY
    Net income $38.6M reported

    What changed

    • Revenue reported to $127.4M; EPS reported to $0.48.
    • Operating income +216% YoY to $63.7M.

    Guidance / outlook

    we expect will meaningfully expand our long-term revenue opportunity.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 14, 2026 SEC filing 8-K May 14, 2026 SEC filing CURRENT REPORT Mar 05, 2026 SEC filing ANNUAL REPORT Mar 05, 2026 Earnings release PRESS RELEASE DATED MARCH 5, 2026 Mar 05, 2026 SEC filing CURRENT REPORT Jan 08, 2026 Earnings release PRESS RELEASE ISSUED BY CORMEDIX INC., DATED JANUARY 8, 2026 Jan 08, 2026 Earnings release PRESS RELEASE ISSUED BY CORMEDIX INC., DATED JANUARY 8, 2026 Jan 08, 2026 SEC filing QUARTERLY REPORT Nov 12, 2025 Earnings release PRESS RELEASE DATED NOVEMBER 12, 2025 Nov 12, 2025 SEC filing CURRENT REPORT Nov 12, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 4.00/5
    CorMedix Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.05/5
    CorMedix Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    CorMedix Inc CRMD US$657.8m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 0.15/5
    CorMedix Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    CorMedix Inc CRMD US$657.8m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.67/5
    CorMedix Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    CorMedix Inc CRMD US$657.8m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    CorMedix Inc logo

    CorMedix Inc

    US$7.87

    US$27.86

    +254.0% vs price

    US$657.8m

    -6.53%

    -31.62%